Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation

Aftab, Waqas; Gazallo, Juliana; Motabar, Ali; Varadrajan, Padmini; Deedwania, Prakash; Pai, Ramdas G.

doi:10.1055/s-0035-1547373

Cited by 3 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In median 4.9 years of follow-up, the combination treatment resulted in 17% reduction in atherosclerotic events. In another study from Aftab et al 61 in patients of end-stage renal disease (ESRD) on hemodialysis awaiting renal transplant, statin use was associated with a lower mortality (hazard ratio 0.30, 95% confidence interval 0.11, 0.79, p = 0.01) in a multivariate analysis. These data supported the use of statins in CKD including hemodialysis cases which are the high-risk for CV disease.…”

Section: Treatment Recommendationsmentioning

confidence: 97%

Adaptation of 2016 European Society of Cardiology/European Atherosclerosis Society guideline for lipid management to Indian patients – A consensus document

Ray

Sawhney

Das³

et al. 2018

Indian Heart Journal

View full text Add to dashboard Cite

In the year 2016, European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines provided recommendations on dyslipidemia management. The recommendation from these guidelines are restricted to European subcontinent. To adapt the updated recommendations for Indian subset of dyslipidemia, a panel of experts in management of dyslipidemia provided their expert opinions. This document provides expert consensus on adapting 2016 ESC dyslipidemia guidelines recommendations in Indian setting. The document also discussed India-specific relevant literature to support the consensus opinions provided in management of dyslipidemia.

show abstract

Section: Treatment Recommendationsmentioning

confidence: 97%

Adaptation of 2016 European Society of Cardiology/European Atherosclerosis Society guideline for lipid management to Indian patients – A consensus document

Ray

Sawhney

Das³

et al. 2018

Indian Heart Journal

View full text Add to dashboard Cite

show abstract

“…Statin may be warranted for secondary prevention of cardiovascular events or in hemodialysis patients who have a longer life expectancy 12 and in those awaiting kidney transplantation. 13 …”

Section: Introductionmentioning

confidence: 99%

Opinions of nephrologists on the efficacy and tolerance of statins in hemodialysis patients

Budzisz

Nowicki

2016

Renal Failure

View full text Add to dashboard Cite

Large randomized controlled trials have not confirmed the effects of statin therapy on reduction of cardiovascular morbidity and mortality in end-stage kidney disease, despite that statins are still widely prescribed by nephrologists to chronic dialysis patients. The aim of the study was to analyze the attitudes of nephrologists towards statin use in hemodialysis patients. Self-designed questionnaire, containing 18 questions, was distributed among 115 nephrologists. The survey contained description of the results of 3 largest statin trials in nephrology. The questions referred to the interpretation of trial results and the safety and efficacy of statin therapy and dose adjustments required in dialysis patients. 83% among 72 nephrologists who returned the questionnaire prescribed statins to their dialysis patients for secondary prevention of cardiovascular events. 90% prescribed atorvastatin. 64% nephrologists did not modify statin dose at the start of hemodialysis treatment and 47% before elective surgery. Liver disease was indicated as a main reason for dose modification in hemodialysis patients. Statin-induced myopathy was observed by 65% nephrologists and 61% reported a case of increased liver enzymes. 51% of nephrologists did not routinely discuss the possible benefits and risks of statin therapy with their patients. Statins are still widely prescribed and considered safe and effective lipid-lowering therapy in dialysis patients by most nephrologists.

show abstract

Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation

Aziz¹,

Garg²,

Parajuli³

et al. 2018

Clinical Transplantation

View full text Add to dashboard Cite

Dyslipidemias are highly prevalent in chronic kidney disease, end‐stage renal disease, and kidney transplant patients. These dyslipidemias are associated with high cardiovascular risk and mortality. Many clinical trials have shown that statin therapy can significantly reduce adverse cardiovascular events in chronic kidney disease patients and kidney transplant recipients. However, three major trials did not show a benefit of statin therapy in end‐stage renal disease patients on dialysis. Major guidelines either recommend against the use of statins in patients on dialysis or provide no recommendations about statin use for this complex patient population. As a result, we suspect many patients on dialysis are not on statins, even if they have known atherosclerotic cardiovascular disease. When these patients receive kidney transplants, the risk of adverse cardiovascular events increases in the peri‐operative period. Although there are no randomized clinical trials looking at statin use in these patients, we suggest that statin use be considered in patients with a history of atherosclerotic cardiovascular disease, to potentially minimize peri‐operative cardiovascular complications. We also recommend further research to determine whether statin therapy in dialysis patients awaiting kidney transplant is associated with better survival.

show abstract

Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation

Cited by 3 publications

References 46 publications

Adaptation of 2016 European Society of Cardiology/European Atherosclerosis Society guideline for lipid management to Indian patients – A consensus document

Adaptation of 2016 European Society of Cardiology/European Atherosclerosis Society guideline for lipid management to Indian patients – A consensus document

Opinions of nephrologists on the efficacy and tolerance of statins in hemodialysis patients

Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation

Contact Info

Product

Resources

About